...
【24h】

Surgery after induction chemoradiotherapy for oesophageal cancer.

机译:食道癌的诱导放化疗后的手术。

获取原文
获取原文并翻译 | 示例

摘要

AIM: We discuss the role of surgery after induction chemoradiotherapy, when a complete response is apparent.METHODS: We enrolled 247 consecutive patients who underwent chemoradiotherapy and oesophagectomy for cancer. Patients were classified in two groups as to whether they had chemoradiotherapy (n=60) or not (n=187) before surgery.RESULTS: The 5-year survival rate of patients with complete response was 54% and was significantly higher than that of the other group (P=0.018). Of the 60 patients responding, 34 (56.7%) were found to have a complete pathological tumour response (pT0). The overall sensitivity and specificity of the post-chemoradiotherapy restaging were 60.7% and 86.4%.CONCLUSIONS: Complete response after induction chemoradiotherapy is not a reliable tool in the management of oesophageal cancer. We need to improve postchemoradiotherapy restaging to be sure that chemoradiotherapy will provide the same long-term survival rates as surgery.
机译:目的:我们讨论诱导化学放疗后手术的作用,当出现完全反应时。方法:我们招募了247例接受化学放疗和食管切除术治疗癌症的连续患者。患者在手术前是否进行放化疗(n = 60)(n = 187)分为两组。结果:完全缓解的患者的5年生存率为54%,显着高于未接受放化疗的患者。另一组(P = 0.018)。在60例有反应的患者中,有34例(56.7%)被发现具有完全的病理性肿瘤反应(pT0)。结论放化疗后分期的总体敏感性和特异性分别为60.7%和86.4%。结论:诱导放化疗后的完全缓解并不是食管癌治疗的可靠工具。我们需要改善放化疗后的分期,以确保放化疗将提供与手术相同的长期生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号